Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Tenets of PTEN Tumor Suppression

Leonardo Salmena, Arkaitz Carracedo, Pier Paolo Pandolfi · Cell · 2008 · 1K citations · Full text

Medicine, Cancer Biology, Oncology +12

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Steven D. Knight, Nicholas D. Adams, Joelle L. Burgess et al. · ACS Medicinal Chemistry Letters · 2010 · 372 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

Daniel P. Sutherlin, Linda Bao, Megan Berry et al. · Journal of Medicinal Chemistry · 2011 · 217 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells

Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal et al. · Cancer Research · 2014 · 128 citations

Medicine, Oncology, Pharmacology +17